06/23/22 4:30 PMAMEX, Nasdaq : OGEN, BWV, CRXT managementOragenics Appoints Seasoned Vaccine Executive Kimberly Murphy as President and Chief Executive OfficerOragenics, Inc., a biotech company dedicated to fighting infectious diseases including coronaviruses, announces the appointment of Ms. Ms. Murphy brings more than 25 years of vaccine industry experience at leading pharmaceutical companies including serving as a key leader in the successful US and Global launch of Merck’ s HPV/Gardasil Franchise.RHEA-AIvery positive
06/09/22 9:05 AMNasdaq : CRXT, CRXTW conferencesClarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at ENDO 2022, the Endocrine Society’s Annual MeetingClarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceuticalRHEA-AIneutral
05/18/22 9:05 AMNasdaq : CRXT, CRXTW Clarus Therapeutics Announces Issuance of Patent Covering JATENZO® (testosterone undecanoate)JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions Clarus plans to list this patent in FDA’s Orange Book, which would bring the total number of Orange Book-listed patents coveringRHEA-AIneutral
05/16/22 4:05 PMNasdaq : CRXT, CRXTW Clarus Therapeutics Reports First Quarter 2022 Financial and Operating ResultsRHEA-AIneutral
05/12/22 9:05 AMNasdaq : CRXT, CRXTW conferencesClarus Therapeutics to Report First Quarter 2022 Financial and Operating ResultsClarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced it will release itsRHEA-AIneutral
05/10/22 9:05 AMNasdaq : CRXT, CRXTW Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering CLAR-121 (Testosterone + Anastrozole) for Treatment of Androgen-Mediated Autoimmune Inflammatory MastitisInitial focus for CLAR-121 is the treatment of periductal mastitis (PDM) in women Clarus is seeking Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in the second quarter of 2022 Initiation of Phase 2 clinical trial for CLAR-121 for the treatment of PDM anticipated in theRHEA-AIneutral
05/09/22 9:05 AMNasdaq : CRXT, CRXTW conferencesClarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at the 2022 American Urological Association Annual MeetingClarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceuticalRHEA-AIneutral
04/28/22 9:05 AMNasdaq : CRXT, CRXTW Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering JATENZO® (testosterone undecanoate)JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions Upon issuance, this patent will be listed in FDA’s Orange Book, bringing the total number of Orange Book-listed patents coveringRHEA-AIneutral
04/27/22 1:43 PMNasdaq : CRXT, CRXTW offeringClarus Therapeutics Announces Closing of Upsized $30.0 Million Underwritten Public OfferingClarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced the closing of itsRHEA-AIneutral
04/25/22 9:20 AMNasdaq : CRXT, CRXTW offeringClarus Therapeutics Announces Pricing of Upsized $30.0 Million Underwritten Public OfferingClarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced the pricing of itsRHEA-AIneutral
